AstraZeneca (LON:AZN) Insider Acquires £303,025 in Stock

AstraZeneca PLC (LON:AZN) insider Michel Demare bought 2,500 shares of the stock in a transaction dated Monday, September 14th. The shares were acquired at an average price of £121.21 per share, for a total transaction of £303,025.

AstraZeneca Stock Performance

LON:AZN traded down GBX 64 during midday trading on Tuesday, reaching £120.90. The stock had a trading volume of 71,305,945 shares, compared to its average volume of 32,175,939. AstraZeneca PLC has a 12-month low of £107.84 and a 12-month high of £157.32. The firm has a fifty day simple moving average of £122.84 and a two-hundred day simple moving average of £135.11. The stock has a market cap of £187.50 billion, a P/E ratio of 18.10, a P/E/G ratio of 0.86 and a beta of 0.20. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. Berenberg Bank dropped their price objective on shares of AstraZeneca from £160 to £150 and set a “buy” rating for the company in a research note on Tuesday. Citigroup boosted their price target on AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a £117 price objective on shares of AstraZeneca in a research note on Tuesday. Jefferies Financial Group reiterated a “buy” rating and set a £175 price objective on shares of AstraZeneca in a research report on Wednesday, September 9th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a £145 target price on shares of AstraZeneca in a report on Tuesday, September 8th. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, AstraZeneca currently has an average rating of “Moderate Buy” and an average price target of £150.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.